USA - engelska - NLM (National Library of Medicine)

gland pharma limited - docetaxel anhydrous (unii: 699121phca) (docetaxel anhydrous - unii:699121phca) - docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. docetaxel injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced ga

USA - engelska - NLM (National Library of Medicine)

xiromed llc - docetaxel anhydrous (unii: 699121phca) (docetaxel anhydrous - unii:699121phca) - docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. docetaxel injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced ga

USA - engelska - NLM (National Library of Medicine)

alembic pharmaceuticals inc. - docetaxel anhydrous (unii: 699121phca) (docetaxel anhydrous - unii:699121phca) - docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. docetaxel injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced ga

USA - engelska - NLM (National Library of Medicine)

alembic pharmaceuticals limited - docetaxel anhydrous (unii: 699121phca) (docetaxel anhydrous - unii:699121phca) - docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. docetaxel injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced ga

USA - engelska - NLM (National Library of Medicine)

sagent pharmaceuticals - docetaxel anhydrous (unii: 699121phca) (docetaxel anhydrous - unii:699121phca) - docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. docetaxel injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with advanced ga

USA - engelska - NLM (National Library of Medicine)

auromedics pharma llc - docetaxel anhydrous (unii: 699121phca) (docetaxel anhydrous - unii:699121phca) - docetaxel injection is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior chemotherapy. docetaxel injection in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node-positive breast cancer. docetaxel injection as a single agent is indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer after failure of prior platinum-based chemotherapy. docetaxel injection in combination with cisplatin is indicated for the treatment of patients with unresectable, locally advanced or metastatic non-small cell lung cancer who have not previously received chemotherapy for this condition. docetaxel injection in combination with prednisone is indicated for the treatment of patients with metastatic castration-resistant prostate cancer. docetaxel injection in combination with cisplatin and fluorouracil is indicated for the treatment of patients with a

Israel - engelska - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - docetaxel - solution for infusion - docetaxel 10 mg / 1 ml - docetaxel - docetaxel - breast cancer: docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease. docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an anthracycline. doxorubicin and cyclophosphamide followed by docetaxel in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with her2 over-expressing, node-positive or high risk node-negative, breast cancer. docetaxel in combination with trastuzumab, and carboplatin (tch) is indicated for the adjuvant treatment of patients with her2 over-expressing, node-positive or high risk node-negative, breast cancer. non-small cell lung cancer: docetaxel is indicated for the treatment of patients with advanced non-small cell lung carcinoma. ovarian cancer: docetaxel is indicated for treatment of metastatic carcinoma of the ovary after failure of first line or subsequent chemotherapy. prostate cancer: docetaxel in combination with prednisone or prednisolone is indicated for the treatment of patients with hormone refractory metastatic prostate cancer.esophageal cancer: docetaxel for the treatment of esophageal cancer. gastric cancer: docetaxel for the treatment of advanced gastric cancer. head and neck (scchn): docetaxel as monotherapy in the treatment of patients with recurrent and/or metastasis squamos cell carcinoma of the head and neck after failure of a previous chemotherapy regimen. docetaxel in combination with cisplatin and 5 fluorouracil is indicated for the induction treatment of patients with locally advanced squamous cell carcinoma of the head and neck

Israel - engelska - Ministry of Health

novartis israel ltd - docetaxel - concentrate for solution for infusion - docetaxel 10 mg / 1 ml - docetaxel - docetaxel - breast cancer: docetaxel in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with operable node- positive breast cancer. docetaxel in combination with doxorubicin is indicated for the treatment of patients with locally advanced or metastatic breast cancer who have not previously received cytotoxic therapy for this condition. docetaxel monotherapy is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic therapy. previous chemotherapy should have included an anthracycline or an alkylating agent. docetaxel in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumors overexpress her2 and who previously have not received chemotherapy for metastatic disease. docetaxel in combination with capecitabine is indicated for the treatment of patients with metastatic breast cancer after failure of cytotoxic chemotherapy. previous therapy should have included an an

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - docetaxel, quantity: 80 mg - injection, concentrated - excipient ingredients: ethanol; polysorbate 80; citric acid; nitrogen - docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel sandoz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. docetaxel sandoz in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease. docetaxel sandoz in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. doxorubicin and cyclophosphamide followed by docetaxel sandoz in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel sandoz in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of =1cm and < 7cm. docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer, including those who have failed platinum-based chemotherapy. docetaxel sandoz is indicated for the treatment of metastatic carcinoma of the ovary after failure of firstline or subsequent chemotherapy. docetaxel sandoz is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer. docetaxel sandoz, in combination with cisplatin and fluorouracil is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.

Australien - engelska - Department of Health (Therapeutic Goods Administration)

sandoz pty ltd - docetaxel, quantity: 20 mg - injection, concentrated - excipient ingredients: polysorbate 80; citric acid; ethanol; nitrogen - docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic breast cancer in whom previous chemotherapy has failed. docetaxel sandoz in combination with capecitabine is indicated for the treatment of patients with locally advanced or metastatic breast cancer after failure of prior anthracycline containing chemotherapy. docetaxel sandoz in combination with trastuzumab is indicated for the treatment of patients with metastatic breast cancer whose tumours overexpress her2 and who previously have not received chemotherapy for metastatic disease. docetaxel sandoz in combination with doxorubicin and cyclophosphamide is indicated for the adjuvant treatment of patients with node-positive breast cancer. doxorubicin and cyclophosphamide followed by docetaxel sandoz in combination with trastuzumab (ac-th) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel sandoz in combination with carboplatin and trastuzumab (tch) is indicated for the adjuvant treatment of patients with operable breast cancer whose tumours overexpress her2. docetaxel in combination with cyclophosphamide is indicated for the adjuvant treatment of operable breast cancer with a primary tumour of =1cm and < 7cm. docetaxel sandoz is indicated for the treatment of patients with locally advanced or metastatic non small cell lung cancer, including those who have failed platinum-based chemotherapy. docetaxel sandoz is indicated for the treatment of metastatic carcinoma of the ovary after failure of firstline or subsequent chemotherapy. docetaxel sandoz is indicated for the treatment of patients with androgen independent (hormone refractory) prostate cancer. docetaxel sandoz, in combination with cisplatin and fluorouracil is indicated as induction treatment prior to chemoradiotherapy, for the treatment of patients with locally advanced, squamous cell carcinoma of the head and neck, who have low probability of surgical cure, require organ preservation or where the tumour is technically unresectable.